Navigation Links
Research findings expected to ease treatment of low neutrophil counts in cancer patients
Date:3/10/2010

For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy.

"Cool," Sabrina told Sheri Spunt, M.D., an associate member of the St. Jude Department of Oncology, after hearing the news and breaking into what Sabrina called her "happy dance." Sabrina is battling rhabdomyosarcoma.

Spunt is Sabrina's doctor and lead author of a study expected to transform how children like Sabrina are treated for neutropenia. Neutropenia is the dangerous drop in white blood cells that leaves cancer patients at increased risk for infections and can delay chemotherapy. The work appears in the March 10 edition of the Journal of Clinical Oncology.

In a study of 44 young cancer patients, investigators reported that the drugs pegfilgrastim and filgrastim were similarly safe and effective at restoring a safe level of neutrophils following chemotherapy. But pegfilgrastim treatment required a single injection, while filgrastim involved daily injections for a week or longer. The trial was a multicenter, randomized, open-label study to evaluate the safety and efficacy of the two drugs as well as how they are used and metabolized in the body.

"This study will make a big impact on the quality of life for patients and their families," Spunt said.

Both drugs are synthetic growth factors designed to stimulate production of neutrophils. Neutrophils are made in the bone marrow and protect against bacterial and fungal infections. They are often short-term casualties of chemotherapy. Filgrastim has been widely used to speed neutrophil recovery. Pegfilgrastim was developed as a longer-acting version of filgrastim. It is approved for use in adults.

Although the study focused on patients with sarcomas such as rhabdomyosarcoma and Ewing sarcoma, Spunt said the results will likely change neutropenia treatment for all childhood cancer patients. The study's participants ranged in age from 28 days to 21 years.

"A large percentage of childhood cancer patients get growth factor support during their therapy," Spunt explained. "The injections are painful for patients and difficult for parents, especially the parents of young children who often need two adults to administer the drug daily. The burdens of therapy for them are considerable."

Sabrina, who did not participate in this study, said she became accustomed to the daily shots administered by her grandmother, Alice Spence. But Sabrina always held tight to her mother's hand when the time came. She was happy when the daily injections were replaced by a single shot.

In the study, researchers reported that after the first round of chemotherapy with vincristine, doxorubicin and cyclophosphamide, neutrophil levels started to rise in half the patients five days after treatment with pegfilgrastim, compared with six days for the filgrastim group. By the third round of chemotherapy, which followed additional treatment with ifosfamide and etoposide, half the patients in both groups were improving in seven days.

Both pegfilgrastim and filgrastim are made by Amgen, a California-based pharmaceutical company. Filgrastim is metabolized in the kidneys. Pegfilgrastim includes a polyethylene glycol tail and is broken down by neutrophils. As a result, pegfilgrastim levels drop as the patient's neutrophils climb.


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Related medicine news :

1. International Iridoid Research Council Announced
2. 2010 Recipient of Minority Scholar Award Will Conduct Clinical Research on Leukemia
3. 2010 recipient of Minority Scholar Award will conduct clinical research on leukemia
4. AdMeTech Praises Rep. Cummings for Introducing $650 Million Prostate Research Bill
5. National Event Addresses Breakthroughs in Crohn's & Colitis Research: National Expert & Researcher Answers Key Questions on Interactive Webcast/Teleconference
6. Research Indicates First Time Trade Show Attendees Unable to Select the Best Display Systems to Match their Budgets -- Alta Graphics Provides the Answers
7. Researcher presents risk-free treatment for low female sexual desire
8. Editorial: Eye cancer research becomes a collaborative pursuit
9. Novel program translates behavioral and social science research into treatments to reduce obesity
10. Exposure to BPA may cause permanent fertility defects, Yale researchers find
11. MRI finds tumors in second breast of women diagnosed with cancer in one breast, Mayo researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... PA (PRWEB) , ... May 21, 2017 , ... Following ... 2012, New York became the first state to require that hospitals follow a protocol ... controversy in the medical community as to whether such steps would have saved Rory ...
(Date:5/19/2017)... ... 19, 2017 , ... DMG Productions is proud to announce ... Ed Begley, Jr., airing fourth quarter 2017 on FOX Business. , Based in ... supplement made from naturally occurring ingredients. Innovations will enlighten viewers on RawTrition’s all-in-one ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Miller Agency, ... to families and business owners in the region, is embarking on a cooperative ... and their families. , Multiple sclerosis (MS) is a demyelinating disease that affects ...
(Date:5/19/2017)... ... May 18, 2017 , ... ML Billing, 2016 ... specialties and sizes and specializes in large group practices, is pleased to announce their ... it has also set the standard in all aspects of full-service medical billing. This ...
(Date:5/18/2017)... ... 18, 2017 , ... Dr. Kim Ross supports Stroke Awareness Month by now ... link between this condition and serious systemic health conditions including heart disease and stroke. ... in Annapolis, MD, and seeking treatment with Dr. Ross immediately may prevent bacteria from ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... 2017  A new tight-tolerance microextrusion medical tubing ... materials, is being launched by Natvar, a Tekni-Plex ... in recent years to service a wide variety ... More expensive materials such as glass and fluoropolymers ... to their ability to consistently hold tolerances. This ...
(Date:5/3/2017)... Calif. , May 3, 2017 ... of any hospital or healthcare facility. Commonly referred ... room is equipped with diagnostic imaging technology to ... of the heart. In these spaces, a team ... catheterization, balloon angioplasty, percutaneous coronary intervention, congenital heart ...
(Date:5/3/2017)... , May 3, 2017  Getinge, a ... contribute to quality enhancement and cost efficiency within ... a study of contemporary practice demonstrating that intra-aortic ... therapy for critically ill patients. The single-center, retrospective, ... newer large volume MEGA ® 50cc intra-aortic ...
Breaking Medicine Technology: